JW Pharmaceutical
JW Pharmaceutical has presented positive preclinical data on JW0061, a novel Wnt-targeted hair loss treatment, at the U.S. Society of Investigative Dermatology meeting. What are Wnt-Targeted Hair Loss Treatments? Wnt-targeted hair loss treatments aim to modulate the Wnt/ß-catenin signaling pathway, which plays an important role in hair follicle development, hair growth cycle regulation, and hair…
Read More
As we head into Q2 2023, the hair growth treatment industry continues to develop and make progress in various ways. Kintor Begins Phase 2 Trial For GT20029 Drug This news appeared one day following the publishing of this article. Kintor Pharmaceutical of China has dosed the first patient in a trial which will comprise 180…
Read More
Korean company JW Pharmaceutical announces that it will participate in the upcoming Wnt 2022 Conference to unveil hair growth related data. JW0061 Pipeline Drug For Hair Loss Since 2017, it’s been known that the Wnt pathway specialists at JW Pharmaceutical had their sights set on hair regeneration. It was announced in the media that the company…
Read More